Feb. 3, 2009 - Tibotec Pharmaceuticals announced today that the European Commission approved once-daily dosing of 800 mg PREZISTA(R) (darunavir), a protease inhibitor, with low-dose ritonavir as part of combination therapy in treatment-naïve adults (those who have never taken HIV medication before).
The details can be read here.
No comments:
Post a Comment